1 veness to treatment with levodopa-carbidopa (Sinemet).

2 ecrease in adverse responses seen at the mid-Sinemet (250 mg levodopa-25 mg carbidopa) dose level.

3                              The response to Sinemet did not change after intracerebroventricular veh

4         The present study has evaluated GDNF-Sinemet interactions in parkinsonian rhesus monkeys.

5                                              Sinemet is currently the most widely used drug for treat

6 , to treatment with either low- or high-dose Sinemet (levodopa plus carbidopa) for 2 weeks and compar

7 nation with a suprathreshold dose of L-DOPA (Sinemet(R)) in 22 patients with Parkinson's disease (16

8                         Adverse responses to Sinemet treatment alone in parkinsonian animals included

9                          Thus, combined GDNF-Sinemet treatment could be of therapeutic value in treat

10 could provide early detection of DR and that Sinemet treatment may reverse retinal dysfunction.

11                                Combined GDNF-Sinemet treatment significantly reduced the occurrence o

12                             After 2 weeks of Sinemet treatment, OP implicit times were restored to co

13 ponse and by mitigating adverse responses to Sinemet treatment.

14                                Both GDNF and Sinemet, when given alone, significantly improved total